Literature DB >> 28431198

Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis.

Gianluca Rompianesi1, Angus Hann2, Oluyemi Komolafe3, Stephen P Pereira4, Brian R Davidson5, Kurinchi Selvan Gurusamy5.   

Abstract

BACKGROUND: The treatment of people with acute abdominal pain differs if they have acute pancreatitis. It is important to know the diagnostic accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary amylase for the diagnosis of acute pancreatitis, so that an informed decision can be made as to whether the person with abdominal pain has acute pancreatitis. There is currently no Cochrane review of the diagnostic test accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary amylase for the diagnosis of acute pancreatitis.
OBJECTIVES: To compare the diagnostic accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary amylase, either alone or in combination, in the diagnosis of acute pancreatitis in people with acute onset of a persistent, severe epigastric pain or diffuse abdominal pain. SEARCH
METHODS: We searched MEDLINE, Embase, Science Citation Index Expanded, National Institute for Health Research (NIHR HTA and DARE), and other databases until March 2017. We searched the references of the included studies to identify additional studies. We did not restrict studies based on language or publication status, or whether data were collected prospectively or retrospectively. We also performed a 'related search' and 'citing reference' search in MEDLINE and Embase. SELECTION CRITERIA: We included all studies that evaluated the diagnostic test accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary amylase for the diagnosis of acute pancreatitis. We excluded case-control studies because these studies are prone to bias. We accepted any of the following reference standards: biopsy, consensus conference definition, radiological features of acute pancreatitis, diagnosis of acute pancreatitis during laparotomy or autopsy, and organ failure. At least two review authors independently searched and screened the references located by the search to identify relevant studies. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data from the included studies. The thresholds used for the diagnosis of acute pancreatitis varied in the trials, resulting in sparse data for each index test. Because of sparse data, we used -2 log likelihood values to determine which model to use for meta-analysis. We calculated and reported the sensitivity, specificity, post-test probability of a positive and negative index test along with 95% confidence interval (CI) for each cutoff, but have reported only the results of the recommended cutoff of three times normal for serum amylase and serum lipase, and the manufacturer-recommended cutoff of 50 mg/mL for urinary trypsinogen-2 in the abstract. MAIN
RESULTS: Ten studies including 5056 participants met the inclusion criteria for this review and assessed the diagnostic accuracy of the index tests in people presenting to the emergency department with acute abdominal pain. The risk of bias was unclear or high for all of the included studies. The study that contributed approximately two-thirds of the participants included in this review was excluded from the results of the analysis presented below due to major concerns about the participants included in the study. We have presented only the results where at least two studies were included in the analysis.Serum amylase, serum lipase, and urinary trypsinogen-2 at the standard threshold levels of more than three times normal for serum amylase and serum lipase, and a threshold of 50 ng/mL for urinary trypsinogen-2 appear to have similar sensitivities (0.72 (95% CI 0.59 to 0.82); 0.79 (95% CI 0.54 to 0.92); and 0.72 (95% CI 0.56 to 0.84), respectively) and specificities (0.93 (95% CI 0.66 to 0.99); 0.89 (95% CI 0.46 to 0.99); and 0.90 (95% CI 0.85 to 0.93), respectively). At the median prevalence of 22.6% of acute pancreatitis in the studies, out of 100 people with positive test, serum amylase (more than three times normal), serum lipase (more than three times normal), and urinary trypsinogen (more than 50 ng/mL), 74 (95% CI 33 to 94); 68 (95% CI 21 to 94); and 67 (95% CI 57 to 76) people have acute pancreatitis, respectively; out of 100 people with negative test, serum amylase (more than three times normal), serum lipase (more than three times normal), and urinary trypsinogen (more than 50 ng/mL), 8 (95% CI 5 to 12); 7 (95% CI 3 to 15); and 8 (95% CI 5 to 13) people have acute pancreatitis, respectively. We were not able to compare these tests formally because of sparse data. AUTHORS'
CONCLUSIONS: As about a quarter of people with acute pancreatitis fail to be diagnosed as having acute pancreatitis with the evaluated tests, one should have a low threshold to admit the patient and treat them for acute pancreatitis if the symptoms are suggestive of acute pancreatitis, even if these tests are normal. About 1 in 10 patients without acute pancreatitis may be wrongly diagnosed as having acute pancreatitis with these tests, therefore it is important to consider other conditions that require urgent surgical intervention, such as perforated viscus, even if these tests are abnormal.The diagnostic performance of these tests decreases even further with the progression of time, and one should have an even lower threshold to perform additional investigations if the symptoms are suggestive of acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28431198      PMCID: PMC6478262          DOI: 10.1002/14651858.CD012010.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  381 in total

1.  [Prognostic role trypsinogen-activating peptide in an acute pancreatitis].

Authors:  A A Pereiaslov
Journal:  Klin Khir       Date:  1999

Review 2.  The role of infection in acute pancreatitis.

Authors:  S W Schmid; W Uhl; H Friess; P Malfertheiner; M W Büchler
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

3.  Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis.

Authors:  P A Testoni; F Bagnolo; S Caporuscio; F Lella
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

4.  [Acute pancreatitis. Etiology, diagnosis, prognosis].

Authors:  B Millat
Journal:  Rev Prat       Date:  1999-02-01

5.  Twenty-four-hour serum amylase predicting pancreatic reaction after endoscopic sphincterotomy.

Authors:  P A Testoni; S Caporuscio; F Bagnolo; F Lella
Journal:  Endoscopy       Date:  1999-02       Impact factor: 10.093

Review 6.  Amylase and lipase in the emergency department evaluation of acute pancreatitis.

Authors:  R J Vissers; R B Abu-Laban; D F McHugh
Journal:  J Emerg Med       Date:  1999 Nov-Dec       Impact factor: 1.484

7.  Simultaneous serum assays of lipase and interleukin-6 for early diagnosis and prognosis of acute pancreatitis.

Authors:  R Pezzilli; A M Morselli-Labate; R Miniero; B Barakat; M Fiocchi; O Cappelletti
Journal:  Clin Chem       Date:  1999-10       Impact factor: 8.327

8.  Evaluation of prognostic factors in patients with acute pancreatitis.

Authors:  G Brisinda; G Maria; A Ferrante; I M Civello
Journal:  Hepatogastroenterology       Date:  1999 May-Jun

9.  Evaluation of a new urinary amylase test strip in the diagnosis of acute pancreatitis.

Authors:  J Hedström; E Svens; P Kenkimäki; E Kemppainen; P Puolakkainen; R Haapiainen; U H Stenman
Journal:  Scand J Clin Lab Invest       Date:  1998-12       Impact factor: 1.713

Review 10.  [Macroamylasemia in the differential diagnosis of acute pancreatitis].

Authors:  J Domènech Calvet; J J Sánchez Cano; A Sánchez Marín; J Sánchez Pérez; F Guspí Saiz; N Bertran Llusà; D del Castillo Déjardin
Journal:  Rev Clin Esp       Date:  1999-07       Impact factor: 1.556

View more
  20 in total

Review 1.  Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.

Authors:  Rasmus M Christensen; Christian R Juhl; Signe S Torekov
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 2.  Total pancreatectomy for recurrent acute and chronic pancreatitis: a critical review of patient selection criteria.

Authors:  Mahya Faghih; Francisco Garcia Gonzalez; Martin A Makary; Vikesh K Singh
Journal:  Curr Opin Gastroenterol       Date:  2017-09       Impact factor: 3.287

3.  Response to Culetto et al.

Authors:  Niloofar Y Jalaly; David C Whitcomb; Vikesh K Singh
Journal:  Am J Gastroenterol       Date:  2018-04       Impact factor: 10.864

4.  Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Recurrent Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Mark E Lowe; Marc T Goodman; Gregory A Coté; Marshall J Glesby; Mark Haupt; Nicholas J Schork; Vikesh K Singh; Dana K Andersen; Stephen J Pandol; Aliye Uc; David C Whitcomb
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

5.  Acute pancreatitis associated with immunoglobulin A vasculitis: report of fifteen cases.

Authors:  Lina Du; Chang Liu; Xintai Wang; Jing Mu; Yan Yang
Journal:  Clin Rheumatol       Date:  2022-10-05       Impact factor: 3.650

Review 6.  Towards evidence-based and personalised care of acute pancreatitis.

Authors:  Guillermo García-Rayado; Karina Cárdenas-Jaén; Enrique de-Madaria
Journal:  United European Gastroenterol J       Date:  2020-01-22       Impact factor: 4.623

7.  Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size.

Authors:  James J Ross; Clive H Wasserfall; Rhonda Bacher; Daniel J Perry; Kieran McGrail; Amanda L Posgai; Xiaoru Dong; Andrew Muir; Xia Li; Martha Campbell-Thompson; Todd M Brusko; Desmond A Schatz; Michael J Haller; Mark A Atkinson
Journal:  Diabetes       Date:  2021-01-13       Impact factor: 9.461

8.  Morphologic Severity of Acute Pancreatitis on Imaging Is Independently Associated with Opioid Dose Requirements in Hospitalized Patients.

Authors:  Aditya Ashok; Mahya Faghih; Elham Afghani; Javad R Azadi; Nasim Parsa; Christopher Fan; Furqan Bhullar; Francisco G Gonzalez; Niloofar Y Jalaly; Tina Boortalary; Mouen A Khashab; Ayesha Kamal; Venkata S Akshintala; Atif Zaheer; Vikesh K Singh
Journal:  Dig Dis Sci       Date:  2021-04-09       Impact factor: 3.487

9.  TLR3 Ligand PolyI:C Prevents Acute Pancreatitis Through the Interferon-β/Interferon-α/β Receptor Signaling Pathway in a Caerulein-Induced Pancreatitis Mouse Model.

Authors:  Chaohao Huang; Shengchuan Chen; Tan Zhang; Dapei Li; Zhonglin Huang; Jian Huang; Yanghua Qin; Bicheng Chen; Genhong Cheng; Feng Ma; Mengtao Zhou
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 10.  2019 WSES guidelines for the management of severe acute pancreatitis.

Authors:  Ari Leppäniemi; Matti Tolonen; Antonio Tarasconi; Helmut Segovia-Lohse; Emiliano Gamberini; Andrew W Kirkpatrick; Chad G Ball; Neil Parry; Massimo Sartelli; Daan Wolbrink; Harry van Goor; Gianluca Baiocchi; Luca Ansaloni; Walter Biffl; Federico Coccolini; Salomone Di Saverio; Yoram Kluger; Ernest Moore; Fausto Catena
Journal:  World J Emerg Surg       Date:  2019-06-13       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.